Curis, Inc. (NASDAQ:CRIS) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday.

CRIS has been the subject of a number of other reports. Cowen and Company reissued a “buy” rating on shares of Curis in a research note on Monday, May 15th. FBR & Co reaffirmed an “outperform” rating on shares of Curis in a research report on Tuesday, March 7th. Finally, Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. Curis presently has a consensus rating of “Buy” and an average price target of $5.88.

Shares of Curis (NASDAQ CRIS) traded down 0.47% on Thursday, reaching $2.10. The company had a trading volume of 1,349,644 shares. Curis has a one year low of $1.47 and a one year high of $3.72. The company has a 50-day moving average price of $1.82 and a 200-day moving average price of $2.54. The firm’s market cap is $301.92 million.

Curis (NASDAQ:CRIS) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by $0.02. Curis had a negative net margin of 841.05% and a negative return on equity of 163.29%. The business had revenue of $2.13 million during the quarter, compared to analyst estimates of $1.98 million. During the same period in the previous year, the firm posted ($0.07) earnings per share. The firm’s revenue was up 23.1% on a year-over-year basis. On average, analysts expect that Curis will post ($0.40) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/06/24/curis-inc-cris-upgraded-by-valuengine-to-hold.html.

In other news, Director James R. Mcnab sold 146,694 shares of the company’s stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $2.61, for a total transaction of $382,871.34. Following the completion of the transaction, the director now directly owns 912,426 shares of the company’s stock, valued at $2,381,431.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James R. Mcnab sold 76,276 shares of the company’s stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $2.04, for a total value of $155,603.04. Following the transaction, the director now directly owns 879,688 shares of the company’s stock, valued at $1,794,563.52. The disclosure for this sale can be found here. Insiders have sold 450,000 shares of company stock valued at $1,101,973 over the last ninety days. 4.07% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CRIS. Bank of America Corp DE boosted its position in Curis by 58.7% in the first quarter. Bank of America Corp DE now owns 36,348 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 13,448 shares in the last quarter. Prudential Financial Inc. purchased a new position in Curis during the first quarter valued at $105,000. Dynamic Technology Lab Private Ltd purchased a new position in Curis during the fourth quarter valued at $106,000. A.R.T. Advisors LLC purchased a new position in Curis during the fourth quarter valued at $116,000. Finally, Oxford Asset Management purchased a new position in Curis during the fourth quarter valued at $138,000. 51.63% of the stock is owned by institutional investors.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.